Profile data is unavailable for this security.
About the company
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
- Revenue in USD (TTM)120.35m
- Net income in USD-19.80m
- Incorporated1996
- Employees147.00
- LocationRigel Pharmaceuticals Inc611 GATEWAY BOULEVARD, SUITE 900SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 624-1100
- Fax+1 (650) 624-1101
- Websitehttps://www.rigel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gossamer Bio Inc | 0.00 | -172.58m | 162.88m | 135.00 | -- | 6.10 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 164.01m | 93.00 | -- | 158.31 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 164.61m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 164.75m | 22.00 | -- | 3.33 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Renovaro Inc | 0.00 | -41.23m | 166.66m | 12.00 | -- | 1.80 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 166.88m | 84.00 | -- | 7.69 | -- | 47.68 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Mediwound Ltd | 18.69m | -6.72m | 167.53m | 100.00 | -- | 5.15 | -- | 8.97 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.89m | 168.19m | 3.00 | -- | 25.04 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| OptiNose Inc | 70.99m | -35.48m | 169.46m | 132.00 | -- | -- | -- | 2.39 | -0.3162 | -0.3162 | 0.6329 | -0.7705 | 0.5635 | 0.9869 | 2.64 | 537,780.30 | -28.17 | -48.25 | -- | -98.95 | 87.84 | 86.96 | -49.99 | -131.66 | 0.5511 | -1.79 | 2.99 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 171.38m | 101.00 | -- | -- | -- | 6.32 | -0.8755 | -0.8755 | 0.9574 | -- | -- | -- | -- | 268,299.50 | -- | -54.12 | -- | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | -- | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 172.28m | 147.00 | -- | -- | -- | 1.43 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Outlook Therapeutics Inc | 0.00 | -51.50m | 175.67m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
| Alimera Sciences Inc | 80.75m | -21.39m | 182.26m | 159.00 | -- | 3.95 | -- | 2.26 | -2.16 | -2.16 | 3.17 | 0.8819 | 0.8235 | 6.22 | 2.98 | 507,886.80 | -20.53 | -19.08 | -29.94 | -27.37 | 86.58 | 86.80 | -24.93 | -19.55 | 2.31 | -0.1919 | 0.5835 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
Data as of May 31 2024. Currency figures normalised to Rigel Pharmaceuticals Inc's reporting currency: US Dollar USD
44.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 15.36m | 8.76% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 14.40m | 8.21% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 12.53m | 7.14% |
| Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 9.24m | 5.27% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.07m | 5.17% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 5.47m | 3.12% |
| Geode Capital Management LLCas of 31 Mar 2024 | 3.79m | 2.16% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.73m | 2.13% |
| Teachers Advisors LLCas of 31 Mar 2024 | 2.41m | 1.37% |
| Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 2.29m | 1.31% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
